Form 4: Beam Therapeutics' Chief Medical Officer Sells Shares to Cover Tax Obligations

Amy Simon, Chief Medical Officer of Beam Therapeutics, sold shares of common stock to cover tax withholding obligations and pursuant to a pre-arranged trading plan.

Summary

• Amy Simon, the Chief Medical Officer of Beam Therapeutics, sold 502 shares of common stock on July 1, 2024, at a price of $23.76 per share.
• An additional 748 shares were sold on July 2, 2024, at $22.95 per share.
• These sales were executed under a Rule 10b5-1 trading plan.
• The sales covered tax withholding obligations related to the vesting of restricted stock units.
• Following these transactions, Simon directly owns 68,805 shares of Beam Therapeutics common stock.
• A correction was made to the previously reported amount of securities beneficially owned, changing it from 70,060 to 70,055 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document simply reports stock sales by an executive to cover tax obligations, which is a routine event. The use of a 10b5-1 plan adds transparency.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating transparency and avoiding concerns about insider trading based on current non-public information.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, although in this case, it is to cover tax obligations.

Industry Context

Sales by company executives are a common occurrence, especially to cover tax obligations related to equity compensation. The use of a 10b5-1 trading plan is a standard practice to avoid insider trading concerns.

Stakeholder Impact

• The stock sales could have a minor negative impact on shareholders if they perceive it as a lack of confidence by the executive, although the 10b5-1 plan mitigates this concern.

Key Dates